Oct 9, 2026 · 50 min
Experimental autism drug faces funding and access test
Best of the Program | Guests: Matt Bielski & Dr. Eric Bartky | 10/9/26
The episode pairs a contentious discussion of war and political responsibility with firsthand claims about L179, an experimental treatment not yet available outside clinical research.
- 1Matt Bielski describes striking changes in his son Lev’s eye contact, emotional connection, and engagement after receiving L179.
- 2Dr. Eric J. Bartky says earlier trials showed benefits across children and young adults, while emphasizing that Phase 3 testing remains ahead.
- 3The treatment is unavailable commercially, and the guests say substantial funding is needed to advance its clinical development.
Don't miss
Matt Bielski describes the changes he says he observed in his son Lev’s eye contact, emotional connection, and engagement after L179 treatment.
The brief
Glenn Beck opens with the proposed execution of the Fort Hood shooter, then broadens the discussion to Iran, Israel, intervention, and U.S. responsibility for war-related costs.
Matt Bielski describes obtaining experimental drug L179 for his son Lev through Yamo Pharmaceuticals, emphasizing changes in eye contact, emotional connection, and engagement.
Dr. Eric J. Bartky says similar improvements appeared among other autistic patients and discusses whether L179 may reduce fight-or-flight behavior linked to autism symptoms.
Bartky explains that L179 is not commercially available and still requires FDA Phase 3 trials, while describing its proposed mechanism and earlier research.
The guests say thousands of parents have sought information and that roughly $75 million is needed to fund Phase 3 testing, including research involving young adults.